I guess I didn't understand your question, so I answered what I thought you asked. Certainly, I did make a mistake stating that Syneos Health is CRO over MSS mCRC. That was a blunder, and I have to fix the post, so thank you very much Ken.

I thought you asked about the priority #.

What do I think? Based on CytoDyn's history with Amarex, they may be averse to using the same CRO for both trials.